http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020223568-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a819eda0adf22936a52362eeebb9fb4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2306
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-998
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2301
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0637
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00
filingDate 2020-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bee666cff189d189bc35f4e549877956
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ea02ec5dfa08ab5a21d7030086c6866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_880155e4bc9aaf2f0bc2a97883a98505
publicationDate 2020-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2020223568-A1
titleOfInvention Bead-free ex-vivo expansion of human regulatory t cells
abstract The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in adoptive cell therapy. In particular, the present disclosure relates to simplified approaches for the expansion of Tregs ex vivo. Tregs produced in this way are suitable for use in various immunotherapy regimens.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023095802-A1
priorityDate 2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014165581-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017022478-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013184011-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2016179288-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018036345-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394880
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395500
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19649

Total number of triples: 40.